Efficacy analysis
| . | VMP . | S+VMP . |
|---|---|---|
| Evaluable patients in part 2 | 49 | 49 |
| Overall response (CR or PR) per EBMT criteria (95% CI) | 80% (66, 90) | 88% (75, 95) |
| CR (95% CI) | 22% (12, 37) | 27% (15, 41) |
| PR | 57% | 61% |
| ≥VGPR (IMWG) | 51% | 71% |
| MR | 8% | 2% |
| No change | 12% | 10% |
| PD | 0% | 0% |
| . | VMP . | S+VMP . |
|---|---|---|
| Evaluable patients in part 2 | 49 | 49 |
| Overall response (CR or PR) per EBMT criteria (95% CI) | 80% (66, 90) | 88% (75, 95) |
| CR (95% CI) | 22% (12, 37) | 27% (15, 41) |
| PR | 57% | 61% |
| ≥VGPR (IMWG) | 51% | 71% |
| MR | 8% | 2% |
| No change | 12% | 10% |
| PD | 0% | 0% |
MR, minimal response; PD, progressive disease.